Hematologic Malignancy
Primary Central Nervous System Lymphoma
CI-CAN-00003730PCNSLExplore in graph →
Hematologic55 active trials
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003730PCNSLExplore in graph →
Clinical trials
145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (10)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04688151 | Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. | completed | Phase 1 | 22 | National Health Research Institutes, TaiwanOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05036577 | A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL(ORMD2021) | completed | Phase 1 | 13 | Huashan HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07198087 | A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants | completed | Phase 1 | 40 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06714370 | Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Nationwide Study(REVEAL) | completed | — | 24 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT03581942 | Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) | completed | Phase 1 / Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT02315326 | Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | completed | Phase 1 / Phase 2 | 93 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT03703167 | Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) | completed | Phase 1 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04401774 | Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04134117 | Tisagenlecleucel In Primary CNS Lymphoma | completed | Phase 1 | 13 | Matthew J. Frigault, M.D.OTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06115824 | New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen | completed | — | 136 | Huashan HospitalOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05390814 | [18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma(FLUDALOC) | completed | Phase 1 | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06914700 | A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteristics and Laboratory Indicators:(PCNSL，GLIOMA) | completed | — | 800 | Guangdong Provincial People's HospitalOTHER | 0 | Apr 9, 2025 | clinicaltrials |
| NCT03495960 | Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System(FIORELLA) | completed | Phase 2 | 72 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 4 | Jan 30, 2025 | clinicaltrials |
| NCT06454266 | First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen) | completed | Phase 2 | 22 | Ningbo No. 1 HospitalOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT01421524 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | completed | Phase 1 | 271 | CelgeneINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT03255018 | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2023 | clinicaltrials |
| NCT04934579 | Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma | completed | Phase 2 | 17 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT01647971 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 39 | TG Therapeutics, Inc.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT05274139 | Treatment of Primary CNS Lymphoma ( FTD ) | completed | Phase 2 | 20 | Mingzhi ZhangOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT00267865 | Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02669511 | PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | completed | Phase 2 | 21 | PIQUR Therapeutics AGINDUSTRY | 0 | Jul 9, 2019 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT02301364 | Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) | completed | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT00112593 | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | completed | N/A | 5 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00193973 | Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma | completed | Phase 2 | 20 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Feb 17, 2017 | clinicaltrials |
| NCT01158274 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 2 | Nov 7, 2014 | clinicaltrials |
| NCT01231919 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 2 | Apr 29, 2014 | clinicaltrials |
| NCT00499811 | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00293345 | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00348985 | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00005811 | Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment | completed | Phase 2 | 77 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2013 | clinicaltrials |
| NCT00004241 | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00003970 | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00077155 | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00098891 | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials